MiR-224 ameliorates inflammation and symptoms in mouse model of allergic rhinitis by targeting CDK9

Main Article Content

Sang Wang
Lei Wang
Hua Hu
Pin Dong


rhinitis, allergic, microRNAs, cyclin-dependent kinase 9, genetic therapy


Objectives To explore the regulatory effects of microRNA (miRNA)-224 and its potential target gene, cyclin dependent kinase 9 (CDK9), in the pathological process of allergic rhinitis (AR).

Methods To investigate the role of miR-224 and CDK9, it was screened by bioinformatics prediction software and verified by dual-luciferase reporter assay. The mouse model of AR was established by ovalbumin (OVA).The animal models were intervened with miR-224 agomir, negative control agomir, and saline respectively. The symptoms of sneezing and nasal rubbing were recorded. The expressions of miR224, CDK9, and cytokines in the nasal mucosa of different groups were analyzed by rt-PCR or western blotting. Enzyme-linked immunoassay (ELISA) was used to evaluate the levels of IgE and Histamine (HA) in the serum. The infiltration of inflammatory cells in the nasal mucosa was studied by immunohistochemistry. The expression and distribution of CDK9 in the nasal mucosa of mice were revealed by immunofluorescence.

Results In the nasal mucosa of the animal models, the level of miR-224 was downregulated, while that of CDK9 was upregulated. The upregulation of miR-224 by miR-224 agomir reduced the frequencies of nasal rubbing and sneezing, the expression of CDK9, the levels of cytokines, and the concentrations of IgE and HA. Moreover, miR-224 appeared to attenuate the infiltration of inflammatory cells and hypersecretion of glands in the nasal mucosa. The expression of CDK9, which was distributed under the mucosa, especially in the submucosa interstitial tissue, was significantly reduced.

Conclusion MiR-224 affected the pathogenesis of AR by targeting CDK9. It proves that miR-224 could be a novel potential therapeutic target for AR.

Abstract 157 | PDF Downloads 149 HTML Downloads 2 XML Downloads 4


1. Cheng L, Chen J, Fu Q, He S, Li H, Liu Z, et al. Chinese society of allergy guidelines for diagnosis and treatment of allergic rhinitis. Allergy Asthma Immunol Res. 2018;10(4):300–353. 10.4168/aair.2018.10.4.300

2. Verhaeghe B, Gevaert P, Holtappels G, Lukat KF, Lange B, Van Cauwenberge P, et al. Up-regulation of IL-18 in allergic rhinitis. Allergy. 2002;57(9):825–830. 10. 1034/j.1398-9995.2002.23539.x

3. Shaoqing Y, Ruxin Z, Guojun L, Zhiqiang Y, Hua H, Shudong Y, et al. Microarray analysis of differentially expressed microRNAs in allergic rhinitis. Am J Rhinol Allergy. 2011;25(6):e242–e246. 10.2500/ajra.2011.25.3682

4. Li J, Shi J, Pan Y, Zhao Y, Yan F, Li H, et al. Transcription modulation by CDK9 regulates inflammatory genes and RIPK3-MLKL-mediated necroptosis in periodontitis progression. Sci Rep. 2019;9(1):17369. 10.1038/s41598-019-53910-y

5. Zhang J, Li G, Ye X. Cyclin T1/CDK9 interacts with influenza A virus polymerase and facilitates its association with cellular RNA polymerase II. J Virol. 2010;84(24):12619–12627. 10.1128/JVI.01696-10

6. Lu Y, Tang L, Zhang Q, Zhang Z, Wei W. MicroRNA-613 inhibits the progression of gastric cancer by targeting CDK9. Artif Cells Nanomed Biotechnol. 2018;46(5):980–984. 10.1080/21691401.2017.1351983

7. De Falco G, Neri LM, De Falco M, Bellan C, Yu Z, De Luca A, et al. Cdk9, a member of the cdc2-like family of kinases, binds to gp130, the receptor of the IL-6 family of cytokines. Oncogene. 2002;21(49):7464–7470. 10.1038/sj.onc.1205967

8. Datta A, Moitra S, Das P, Mondal S, Omar Faruk S, Hazra I, et al. Allergen immunotherapy modulates sensitivity of Treg cells to apoptosis in a rat model of allergic asthma. 2017;9(15):1239–1251. 10.2217/imt-2017-0038

9. Hellvard A, Zeitlmann L, Heiser U, Kehlen A, Niestroj A, Demuth HU, et al. Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis. Sci Rep. 2016;6:31441. 10.1038/srep31441

10. Schmerwitz UK, Sass G, Khandoga AG, Joore J, Mayer BA, Berberich N, et al. Flavopiridol protects against inflammation by attenuating leukocyte-endothelial interaction via inhibition of cyclin-dependent kinase 9. Arterioscler Thromb Vasc Biol. 2011;31(2):280–288. 10.1161/ATVBAHA.110.213934

11. Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A. Cyclin dependent kinase 9 inhibitors for cancer therapy. J Med Chem. 2016;59(19):8667–8684. 10.1021/acs.jmedchem.6b00150

12. Hu H, Ramezanpour M, Hayes AJ, Liu S, Psaltis AJ, Wormald PJ, et al. Sub-inhibitory clindamycin and azithromycin reduce S. aureus exoprotein induced toxicity, inflammation, barrier disruption and invasion. J Clin Med. 2019;8(10):1617. 10.3390/jcm8101617

13. Ashraf MI, Shahzad M, Shabbir A. Oxyresveratrol ameliorates allergic airway inflammation via attenuation of IL-4, IL-5, and IL-13 expression levels. Cytokine. 2015;76(2):375–381. 10.1016/j.cyto.2015.09.013

14. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014; 6(10): a016295. 10.1101/cshperspect.a016295

15. Ferrante G, Montalbano L, Cilluffo G, Malizia V, Marchese D, La Grutta S. Beclomethasone dipropionate hydrofluoroalkane for the treatment of allergic rhinitis. Expert Rev Clin Immunol. 2016;12(3):279–288. 10.1586/1744666X.2016.1118347

16. Shi Q, Lei Z, Cheng G, Li D, Wang Q, Luo S, et al. Mitochondrial ROS activate interleukin-1beta expression in allergic rhinitis. Oncol Lett. 2018;16(3):3193–3200. 10.3892/ol.2018.8984

17. Liang T-J, Qin C-Y. The emerging role of microRNAs in immune cell development and differentiation. APMIS. 2009;117(9):635–643. 10.1111/j.1600-0463.2009.02520.x

18. Panganiban RP, Wang Y, Howrylak J, Chinchilli VM, Craig TJ, August A, et al. Circulating microRNAs as biomarkers in patients with allergic rhinitis and asthma. J Allergy Clin Immunol. 2016;137(5):1423–1432. 10.1016/j.jaci.2016.01.029

19. Zhang XH, Zhang YN, Liu Z. MicroRNA in chronic rhinosinusitis and allergic rhinitis. Curr Allergy Asthma Rep. 2014;14(2):415. 10.1007/s11882-013-0415-3

20. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. 10.1016/S0092-8674(04)00045-5

21. Teng Y, Zhang R, Yu H, Wang H, Hong Z, Zhuang W, et al. Altered microRNA expression profiles in activated mast cells following IgE-FcεRI cross-linking with antigen. Cell Physiol Biochem. 2015;35(6):2098–2110. 10.1159/000374016

22. Cui X, Guo Y, Wang Q, Li X. MiR-199-3p-Dnmt3a-STAT3 signalling pathway in ovalbumin-induced allergic rhinitis. Exp Physiol. 2019;104(8):1286–1295. 10.1113/EP087751

23. Wang J, Cui Z, Liu L, Zhang S, Zhang Y, Zhang Y, et al. MiR-146a mimic attenuates murine allergic rhinitis by downregulating TLR4/TRAF6/NF-κB pathway. Immunotherapy. 2019; 11(13): 1095–1105. 10.2217/imt-2019-0047

24. Wang L, Liu X, Song X, Dong L, Liu D. MiR-202-5p promotes M2 polarization in allergic rhinitis by targeting MATN2. Int Arch Allergy Immunol. 2019;178(2):119–127. 10.1159/000493803

25. Deng Y-Q, Yang Y-Q, Wang S-B, Li F, Liu M-Z, Hua Q-Q, et al. Intranasal administration of lentiviral miR-135a regulates mast cell and allergen-induced inflammation by targeting GATA-3. PLoS One. 2015;10(9):e0139322. 10.1371/journal.pone.0139322

26. Romano G, Giordano A. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle. 2008;7(23):3664–3668. 10.4161/cc.7.23.7122

27. Ellis AK, Tenn MW. Advances in rhinitis: models and mechanisms. Ann Allergy Asthma Immunol. 2018;121(1):61–64. 10.1016/j.anai.2017.10.008